Global CRM197 Market Growth (Status and Outlook) 2023-2029

Global CRM197 Market Growth (Status and Outlook) 2023-2029

CRM197 is a non-toxic mutant of diphtheria toxin and it's widely used as a carrier protein for conjugate vaccines.

LPI (LP Information)' newest research report, the “CRM197 Industry Forecast” looks at past sales and reviews total world CRM197 sales in 2022, providing a comprehensive analysis by region and market sector of projected CRM197 sales for 2023 through 2029. With CRM197 sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CRM197 industry.

This Insight Report provides a comprehensive analysis of the global CRM197 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CRM197 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CRM197 market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CRM197 and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CRM197.

The global CRM197 market size is projected to grow from US$ 168.5 million in 2022 to US$ 244.4 million in 2029; it is expected to grow at a CAGR of 5.5% from 2023 to 2029.

Pfizer Inc is one of the most important global manufacturers of CRM197, holds a share of over 85%. North America is the largest market, occupied for over 75%. In terms of type, research grade is the largest segment, with a share of over 85%. And in terms of application, pneumococcal conjugate vaccine segment holds a share of about 90%.

This report presents a comprehensive overview, market shares, and growth opportunities of CRM197 market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Research Grade CRM197
cGMP Grade CRM197

Segmentation by application
Pneumococcal Conjugate Vaccine
Meningococcal Polysaccharide Conjugate Vaccine
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer Inc.
Ligand Pharmaceuticals
CanSino Biologic
Beijing Kexing Biology Product
Scarab Genomics
Xpress Biologics
Fina Biosolutions
Eubiologics
EirGenix Inc.

Please note: The report will take approximately 2 business days to prepare and deliver.